UNSPSC 51362301: Cetohexazine

This classification denotes a sedative and hypnotic with the molecular formula C6H8N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NS7PP85V4C, chemically known as 4,6-dimethyl-3(2h)-pyridazinone. but generally known as cetohexazine, which bears US NIH Compound Identifier 193965. European Medicines Agency schedules Cetohexazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07454MIG.

UNSPSC 51362301 Cetohexazine (Commodity) covers pharmaceutical products and related health supply systems procured by state and local health agencies, though the recent solicitations posted under this code reflect a broader procurement landscape dominated by naloxone, drug deactivation systems, and generic multi-source pharmaceuticals rather than cetohexazine specifically. State and local buyers use this code to source controlled-substance management products, emergency response pharmaceuticals, and OTC medications distributed through county health departments, state health commissions, and cooperative purchasing consortia. The work involves product specification and sourcing through authorized wholesalers, compliance with cGMP and drug supply-chain security standards, and delivery logistics to public health facilities. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multi-state purchasing cooperatives (Minnesota Multistate Cooperative Purchasing Alliance serving multiple states including Oregon).

Recent activity spans Florida and multi-state cooperative vehicles centered in the Upper Midwest. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 through MMCAP on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and contract effectiveness July 1, 2026; this cooperative vehicle spans Minnesota, Oregon, and other participating jurisdictions with awards to multiple vendors based on price competitiveness (75 percent weight), fixed pricing (10 percent), and EDI capability (5 percent).